---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004945"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:48:26.621471+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arbutus Q2 revenue $4.7M, net loss $17.1M; AB-101 clears NZ regulatory for Phase 1

## Summary
- Total revenue $4.7M vs $14.2M YoY on lower Qilu license revenue; net loss $17.1M ($0.10 EPS).
- Cash $163.5M; runway into Q1 2025; net cash burn guidance $90-95M for 2023.
- AB-729 (imdusiran) Phase 2a data at EASL: mean HBsAg decline ~1.6 log10; four patients reached below LLOQ.
- AB-101 (oral PD-L1) received NZ Medsafe approval for Phase 1 after FDA clinical hold; dosing starts Q3 2023.
- Melissa Rewolinski appointed to board; Karen Sims promoted to CMO; Christopher Naftzger named GC and CCO.

## SEC filing metadata
- accession: 0001171843-23-004945
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/0001171843-23-004945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/f8k_080223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004945
- JSON: https://secwatch.observer/filing/0001171843-23-004945.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004945.txt

## Key facts
- Earnings Releases
  Arbutus Biopharma Corp reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/0001171843-23-004945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.